The ectopic olfactory receptor OR7A17 regulates the proliferation and differentiation of human epidermal keratinocytes, and ginsenoside Rh3 acts as its antagonist

异位嗅觉受体OR7A17调节人表皮角质形成细胞的增殖和分化,而人参皂苷Rh3是其拮抗剂。

阅读:2

Abstract

BACKGROUND: Olfactory receptors perform diverse functions in many cell types and are ectopically expressed in human epidermis. PURPOSE: This study aimed to examine the role of OR7A17 in keratinocyte biology, its signaling pathway and the potential of ginsenosides as its antagonist. METHODS: OR7A17 function was examined in stably OR7A17-overexpressing HaCaT cells using western blots, image analysis, flow cytometric and qPCR. RESULTS: We found that OR7A17 overexpression promoted keratinocyte proliferation through MAPK signaling pathway, accompanied by elevated cAMP and cytosolic Ca(2+) levels, which activated AP-1 and CRE. Moreover, blockade experiments showed that CNG, TRPV1, and TRPA1 channels mediated these Ca(2+) signals. OR7A17 also promoted the PI3K/AKT pathway, activating NF-κB and driving G1/S cell cycle progression via GSK-3β inhibition and P70S6K activation. Conversely, OR7A17 overexpression repressed differentiation, as evidenced by reduced expression of early and late differentiation markers. Molecular docking and functional assays confirmed that ginsenoside Rh3 bound OR7A17 and antagonized its signaling, thereby inhibiting proliferation and restoring differentiation. CONCLUSION: In summary, OR7A17 promoted keratinocyte proliferation by activating PKA/MAPK, Ca(2+)/CREB, and PI3K-AKT-NF-κB pathways, while repressing differentiation. In addition, ginsenoside Rh3 functioned as an antagonist of OR7A17, counteracting these effects. These findings suggest OR7A17 as a therapeutic target for proliferation- and differentiation-related skin disorders such as atopic dermatitis, with ginsenoside Rh3 as a potential regulator for epidermal homeostasis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。